Categories Editor's Pick

Ghana to produce first locally manufactured vaccine by 2027 

Ghana is expected to produce its first locally manufactured vaccine, the tetanus-diphtheria vaccine, by the first quarter of 2027 as part of efforts to strengthen domestic vaccine production.

The initiative is aimed at reducing reliance on imported vaccines and building the country’s pharmaceutical manufacturing capacity.

Dr Sodzi Sodzi-Tettey, Chief Executive Officer of the National Vaccine Institute (NVI), disclosed this on Wednesday at the commissioning of the National Human Identification Laboratory and the Vaccine Research and Development facilities at the Noguchi Memorial Institute for Medical Research in Accra.

He said preparations for production were progressing steadily, with the first of three bulk substances required for manufacturing the vaccine already in the country.

The substance, manufactured in Indonesia under a grant arrangement negotiated by the Ministry of Health, is currently at the premises of Atlantic Life Sciences.

Dr Sodzi-Tettey said the arrangement was expected to reduce production costs and improve affordability for the Government.

He said the procurement and installation of equipment, as well as the training of scientists for the new mRNA laboratory, had been fully funded by the Government.

The NVI was also collaborating with the Africa Centres for Disease Control and Prevention (Africa CDC) and the International Vaccine Institute to link Ghana’s research activities with other mRNA research hubs across Africa, he said.

Dr Sodzi-Tettey said the recently approved Ghana Pharmaceutical Manufacturing Policy would provide incentives to strengthen local pharmaceutical production and address skills gaps within the industry.

He cited the tax exemption granted on the imported bulk substance for the tetanus-diphtheria vaccine as one of the policy measures supporting local manufacturing.

The Chief Executive Officer said the NVI, in partnership with the Pharmabus Project, would establish the Ghana Biomanufacturing Training Consortium by the end of 2027 to support the training of scientists and industry professionals.

He said the consortium, comprising academic institutions and industry partners, would develop specialised skills in key areas required to support Ghana’s transition from vaccine fill-and-finish operations to end-to-end manufacturing.

 

Dr Sodzi-Tettey said the Minister of Health had finalised a Cabinet memorandum seeking approval for advance market commitments and 10-year procurement agreements to support local vaccine production.

He estimated that Ghana would require at least US$50 million annually for vaccine procurement following its transition from external support arrangements and said part of that expenditure should be directed towards strengthening local manufacturing capacity.

“We need to begin to think in terms of a dedicated fund that would assure the industry that not only are we promising to purchase, but we have the financial backing to continue to purchase,” he said.

Dr Sodzi-Tettey said the proposed arrangements would help retain investment within the country, create jobs and provide a sustainable market for locally manufactured vaccines.

He described the developments as the beginning of a new phase in Ghana’s vaccine and pharmaceutical manufacturing agenda and commended the Minister of Health for supporting efforts to establish a domestic vaccine manufacturing ecosystem.

 

 

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Newest
Oldest Most Voted